---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003933"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:57:54.186664+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback

## Summary
- Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.
- 2024 revenue guidance $600-630 million; cash and investments $425.4M at Dec 31, 2023.
- Board authorized $200M stock repurchase program; effective Jan 10, 2024.
- Results are preliminary, unaudited, and subject to audit adjustments.

## SEC filing metadata
- accession: 0001193125-24-003933
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/d45395d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003933
- JSON: https://secwatch.observer/filing/0001193125-24-003933.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003933.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported year ended December 31, 2023 results: revenue $482.4 million.
  - Period: year ended December 31, 2023
  - Revenue: $482.4 million
  - Result: preliminary results
  source text: Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported quarter ended December 31, 2023 results: revenue $135.4 million.
  - Period: quarter ended December 31, 2023
  - Revenue: $135.4 million
  - Result: preliminary results
  source text: Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported fiscal year 2024 results: revenue $600 – $630 million. Guidance initiated.
  - Period: fiscal year 2024
  - Revenue: $600 – $630 million
  - Guidance: initiated
  - Result: guidance update
  source text: Financial Update • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • 2024 revenue guidance of $600 – $630 million • Cash and investments of $425.4 million as of December 31, 2023 • Announcement of $200 million stock repurchase program “As the true prevalence of hypercortisolism and its devastating impact become better understood, physicians are identifying and treating more patients
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000119312524003933/0001193125-24-003933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.